FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to cardiology. Selection is conducted under the control of multiday telemonitoring (MTM) of ECG with an initial loading dose of 600 to 400 mg AH per day; when two effectiveness criteria or one of the side effects is achieved in the first 7 days of observation, the dose is reduced by 200 mg/day; when one of the following conditions is met in the next 7—10 days of observation: side effects are lost, all quantitative effectiveness criteria are achieved, or antiarrhythmic effect is stabilised, the dose is reduced, determining the maintenance dose as the minimum effective one.
EFFECT: due to the personalised approach, method reduces the loading dose and accelerates the transition to a maintenance dose of AH; provides control over the occurrence of side effects and proarrhythmic effects; has a proven antiarrhythmic effect.
1 cl, 2 ex, 2 tbl
